Temsirolimus and Rituximab in Patients with Relapsed or Refractory Mantle Cell Lymphoma: a multi-center Phase 2 Study

BACKGROUND: Temsirolimus is an mTOR inhibitor with single-agent antitumor activity in patients with mantle cell lymphoma (MCL). We therefore tested the efficacy and toxicity of temsirolimus in combination with rituximab in patients with relapsed or refractory MCL. METHODS: Patients received temsirol...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Hoofdauteurs: Ansell, Stephen M., Tang, Hui, Kurtin, Paul J., Koenig, Patricia A., Inwards, David J., Shah, Keith, Ziesmer, Steven C., Feldman, Andrew L., Rao, Radha, Gupta, Mamta, Erlichman, Charles, Witzig, Thomas E.
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: 2011
Onderwerpen:
Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3106222/
https://ncbi.nlm.nih.gov/pubmed/21440503
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(11)70062-6
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items